False Claims Act Insights - Healthcare Compensation and Referrals: Avoiding Compliance Pitfalls in Physician Deals
DOJ’s Bulk Sensitive Data Transfer Rule: Key Insights for Health Care Compliance Teams – Diagnosing Health Care
Hospice Insights Podcast - High Risk Hospices Are in the Hot Seat Across Six States
Taking The Pulse, A Health Care and Life Sciences Video Podcast | Episode 273: Navigating FDA Regulation for Life Sciences Companies with Christin Carey of Maynard Nexsen
PODCAST – 2026 To Do: HIPAA Compliance
2026 To Do: HIPAA Compliance
Health-E Law Podcast, Episode 24 | ViVE 2026: AI and the Future of Healthcare
Taking The Pulse, A Health Care and Life Sciences Video Podcast | Episode 272: Humanism and Transplant Care with Dr. Joseph Scalea of MUSC
AI in Healthcare: Five Healthcare AI Stories You Need to Know This Week - April 3, 2026
How to Stay HIPAA Compliant When Using Health Care Analytics
PBM Reform 2026: What Recent Legislation Means for the Industry
McDonald Hopkins Legal Diagnosis Podcast, Episode 8: Stark Law
Taking The Pulse, A Health Care and Life Sciences Video Podcast | Episode 271: Advancing Neurotrauma Treatments with Ken Webb of NeuroHope Therapeutics
AI in Healthcare: Five Healthcare AI Stories You Need to Know This Week – March 27, 2026
Health-e Law Podcast, Episode 23 | The Future of Brain Tech With Dr. Newton Howard
Hospice Insights Podcast - What’s New? CMS Provisional Period of Enhanced Oversight Application to “New” Hospices
Taking the Pulse, A Health Care and Life Sciences Video Podcast | Episode 270: Building a Future-Ready Workforce in Life Sciences with Daniel Grove of Lonza
State AGs in Action: Health Care Enforcement in 2026 – Speaking of Litigation Video Podcast
Taking the Pulse, A Health Care and Life Sciences Video Podcast | Episode 269: Investing in Distributed Healthcare with Gordon Maner of Frontline Healthcare Partners
Podcast - States Propose New Laws Affecting Healthcare Real Estate Investors and Owners
Our Drug Pricing and Market Access team tracks recent developments in healthcare reform, the Medicaid Drug Rebate Program, the 340B Program, Medicare, and state law....more
The U.S. Congress remains in session with healthcare activity continuing to center on budget oversight and committee hearings. U.S. Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. is scheduled to...more
ASN leaders meet with members of Congress to urge support for kidney health - The American Society of Nephrology (ASN)’s advocacy delegation met with congressional delegations to request bipartisan support for critical...more
On April 3, 2026, the director of the Office of Management and Budget submitted to Congress President Donald Trump’s budget for 2027—proposing $111.1 billion in discretionary budget authority for the U.S. Department of Health...more
News Briefs - States Step in to Oversee, Regulate Healthcare - They say that nature abhors a vacuum, and, apparently, U.S. healthcare doesn't care for one much, either. Because in the absence of federal legislation and...more
Epstein Becker & Green is pleased to share that the latest edition of our comprehensive 50-State Noncompete Survey has been updated and is now available. This resource reflects the rapidly evolving legal landscape...more
Building on the Trump administration’s efforts to crack down on deceptive direct-to-consumer (DTC) prescription drug advertising, the Food and Drug Administration (FDA) has recently requested new authority from Congress to...more
Virginia is among a growing number of states that have adopted healthcare-specific workplace violence prevention and reporting obligations. On April 6, 2026, Governor Abigail Spanberger signed House Bill (HB) 1489, which...more
In recent years, the Federal Circuit has, with varying levels of agreement, considered what behavior by generic drugmakers constitutes inducement of infringement regarding so-called “off-label” prescribing for indications not...more
Key Points - • In Teva Pharmaceuticals International GmbH v. Eli Lilly & Co., the Federal Circuit upheld broad method of treatment claims directed to using anti-CGRP antagonist antibodies to treat headache, even though...more
This is the sixth and final installment in a six-part series on incentive design, deal structure, and how these issues surface in transactions and enforcement. Other relevant topics will be discussed in our upcoming...more
Signed in March, Executive Order 14395, Establishing the Task Force to Eliminate Fraud, reflects a significant development in how the federal government approaches fraud in federally funded benefit programs.[1]. For...more
Employees who request to work remotely or seek time away from work for medical reasons may implicate multiple employment statutes, including the Americans with Disabilities Act (ADA), the Family and Medical Leave Act (FMLA),...more
In Part One of this series, we discussed how wellness products sit at the intersection of Food and Drug Administration (FDA), Health Insurance Portability and Accountability Act (HIPAA), Federal Trade Commission (FTC), and...more
On April 14, 2026, the Centers for Medicare & Medicaid Services (CMS) published its annual proposed rule for the federal fiscal year (FFY) 2027 Inpatient Prospective Payment System (IPPS) and long-term care hospital (LTCH)...more
This chart summarizes the case name, presiding judge, drug, and patents-at-issue in all federal district court cases that are filed pursuant to the Hatch-Waxman Act....more
After three appearances at congressional committees last week, US Department of Health and Human Services (HHS) Secretary Kennedy will testify in front of four additional committees this week....more
The World Health Organization (WHO) and the Occupational Safety and Health Administration (OSHA) are each addressing an urgent issue in the healthcare industry: workplace violence....more
On 28 April 2026, the Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025 will enter into force, representing the most significant overhaul of UK clinical trials regime in more than two decades....more
On April 7, 2026, Biocon announced the U.S. commercial launch of Bosaya™ / Aukelso™ (denosumab-kyqq), biosimilars of Amgen’s Prolia® / Xgeva® (denosumab). ...more
Effective April 1, 2026, British Columbia’s Health Professions Act (HPA) was repealed and replaced by the Health Professions and Occupations Act (HPOA). The HPOA is the culmination of several years of consultation and reform...more
On April 18, 2026, President Trump signed an Executive Order titled "Accelerating Medical Treatments for Serious Mental Illness," directing multiple federal agencies to accelerate research into, and access to, psychedelic...more
On April 8, 2026, the Department of Health and Human Services’ Office for Civil Rights (OCR) released an educational video, Risk Management Under the HIPAA Security Rule, detailing the risk management requirements under HIPAA...more
With Legislative Bill 921 (LB 921), Nebraska has joined a growing number of states enacting worker protection legislation that exceeds federal standards. The bill addresses two distinct areas: (1) worker notification during...more
IBM to Pay $17 Million for Alleged Discriminatory DEI Practices - On April 10, acting Attorney General Todd Blanche announced the first resolution under the Civil Rights Fraud Initiative, previously launched in May 2025....more
